Eli Lilly's novel eltrekibart shows early promise in hidradenitis suppurativa
NEW ORLEANS — A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment. Eltrekibart (LY3041658, Eli Lilly) is a humanized monoclonal antibody that binds to the seven ligands that signal through CXCR1 and CXCR2, according to Seth Forman, MD,
Source: healio.com